**O-Glycosylation of EGF repeats: identification and initial characterization of a UDP-glucose: protein O-glucosyltransferase**

Li Shao1, Yi Luo1, Daniel J. Moloney1, and Robert S. Haltiwanger2,3

1Department of Biochemistry and Cell Biology, Institute for Cell and Developmental Biology, State University of New York at Stony Brook, Stony Brook, NY 11794-5215, USA
2To whom correspondence should be addressed; E-mail: Robert.Haltiwanger@stonybrook.edu
3Present address: Department of Cell Biology, Albert Einstein College of Medicine, 1300 Morris Park Ave., Bronx, NY 10461, USA

Received on April 17, 2002; revised on June 25, 2002; accepted on July 5, 2002

**O-Glucose is an unusual form of posttranslational modification consisting of glucose directly attached to protein through O-linkage.** Several serum proteins (factor VII, factor IX, protein Z, and thrombospondin) contain this unique modification on their epidermal growth factor (EGF)-like repeats. Comparison of the glycosylation sites on these proteins revealed a putative consensus sequence for O-glucose modification: C1XSXPC2, where C1 and C2 are the first and second conserved cysteines of the EGF repeat. We identify and characterize an enzymatic activity capable of adding glucose to EGF repeats: UDP-glucose:protein O-glucosyltransferase. Using extracts of Chinese hamster ovary cells as the enzyme source, recombinant factor VII EGF repeat as the acceptor, and UDP-[3H]glucose as the donor, we show that the activity is linearly dependent on time, enzyme amount, and substrate concentration. As with most glycosyltransferases, metal ions (such as manganese) are required for activity. Analysis demonstrated that the glucose is added in O-linkage to the EGF repeat. Mutation of the serine to alanine in the predicted glycosylation site abrogates glycosylation, as does reduction and alkylation of the EGF repeat, suggesting that the enzyme recognizes not only the consensus sequence but also the 3D structure of the EGF repeat. Detection of O-glucosyltransferase activity in extracts of cell lines from insects to humans and a variety of rat tissues suggests that O-glucose modification is widespread in biology. These studies lay the foundation for future work on the biological role of the O-glucose modification.

**Key words:** Chinese hamster ovary cells/EGF repeats/glycosyltransferase/glycosyltransferases/O-glucose

**Introduction**

Although O-linked carbohydrate modifications on epidermal growth factor (EGF)-like repeats have only recently been described (Harris and Spellman, 1993), they have generated a great deal of excitement. Two kinds of O-linked structures have been reported consisting of a fucose (O-fucose) or glucose (O-glucose) attached to the EGF repeats through the hydroxyl group of serine or threonine residues. EGF repeats are small motifs with about 40 amino acids defined by 6 conserved cysteines forming three disulfide bonds (Campbell and Bork, 1993). They are well known as players in protein–protein interactions, such as receptor–ligand binding. Recent work in a number of laboratories has demonstrated that such receptor–ligand interactions can be affected by the alterations in the O-linked carbohydrate modifications on EGF repeats. For instance, Fringe is known to be an O-fucose-specific β1,3-N-acetylgalactosaminyltransferase capable of altering Notch signal transduction by addition of GlcNAc residues to O-fucose modifications on the EGF repeats of Notch (Bruckner et al., 2000; Moloney et al., 2000a). Recently, the presence of an O-fucose on the EGF repeat of Cripto was demonstrated to be essential for Cripto to mediate Nodal-dependent signaling (Schiffer et al., 2001; Yan et al., 2002). Coimmunoprecipitation studies suggest that the O-fucose is essential for productive interaction between Cripto and Nodal (Yan et al., 2002). O-fucose on urinary-type plasminogen activator (uPA) also appears to be required for activation of the uPA receptor (Rabbani et al., 1992). Defucosylated EGF repeat from uPA is able to bind to the uPA receptor, but it does not induce stimulation of signaling. Each of these examples demonstrates how alterations in an O-linked carbohydrate modification on an EGF repeat can regulate a signaling event.

The O-glucose modification was originally identified on bovine blood coagulation factors VII and IX (Hase et al., 1988). Detailed analysis demonstrated a trisaccharide form of O-glucose on bovine factor IX with the structure Xyl-α1,3-Xyl-α1,3-Glc-β1-O-Ser (Hase et al., 1990). Similar structures were observed on human factor VII, factor IX, and protein Z (Nishimura et al., 1989). Comparison of the sequences surrounding sites of glycosylation on these proteins led to the proposal of a putative consensus sequence for the O-glucose addition (Harris and Spellman, 1993). The proposed consensus sequence for addition of O-glucose is C1-X-S-X-P-C2, where C1 and C2 are the first and second conserved cysteines of the EGF repeat, respectively, and X can be any amino acid (Harris and Spellman, 1993). The actual number of proteins known to be modified with the O-glucose modification is limited, but the putative consensus sequence allows database searches (Table I) revealing that numerous secreted and cell surface proteins are predicted to bear O-glucose. We recently demonstrated that the putative consensus sequence is capable of accurately predicting whether a protein bears O-glucose by showing that the Notch receptor has this modification (Moloney et al., 2000b) (Table I).
Development of an in vitro assay for the UDP-glucose: protein O-glucosyltransferase

To develop the assay, we utilized UDP-[^3H]glucose as the donor substrate and a bacterially expressed recombinant factor VII EGF repeat known to contain an O-glucose consensus site (Harris and Spellman, 1993) as the acceptor substrate. Extracts of CHO cells were used as the enzyme source because we knew that CHO cells synthesize proteins bearing the O-glucose modification (Moloney et al., 2000b). After incubation of the CHO cell lysate with factor VII EGF repeat and UDP-[^3H]glucose, the products were separated from unincorporated radiolabel using a C18 cartridge. The O-glucosyltransferase activity showed linear dependency on the amount of lysate (Figure 2a), factor VII EGF repeat (Figure 2b), and UDP-glucose (Figure 2c).

Previous studies on the protein O-fucosyltransferase (O-FucT-1) demonstrated that the EGF repeat needed to be properly folded for the enzyme to recognize the consensus site (Wang and Spellman, 1998). To examine whether the O-glucosyltransferase also requires folded EGF repeats, the factor VII EGF repeat was denatured in urea and reduced and alkylated with dithiothreitol (DTT) and iodoacetamide. Control factor VII EGF repeat was treated with urea but not with DTT or iodoacetamide. Both were repurified by reverse-phase high-performance liquid chromatography (HPLC) (Figure 3a), where the reduced and alkylated form migrated somewhat later, consistent with the carboxamidomethylation. Both the denatured and native EGF repeats were analyzed as substrates in the O-glucosyltransferase assay, and only the native EGF repeat was functional (Figure 3b). The reduced and alkylated EGF repeat did not serve as a substrate for the enzyme, even at high concentrations. These results demonstrate that the enzyme requires a properly folded EGF repeat for recognition.

Human factor VII is modified with O-glucose at serine-52 (Hase et al., 1988). To examine whether the predicted serine on the factor VII EGF repeat was being modified, an alanine was substituted for serine-52 (S52A: C1-A-S→C1-A-P-C2). Because the adjacent amino acid is also a serine, it was also mutated to alanine (S53A: C1-A-S→C1-A-S-P-C2) to examine the possibility of its modification. Both the S52A and S53A mutants were expressed in Escherichia coli and purified. Because mutations in EGF repeats can result in misfolding (Wang and Spellman, 1998) and misfolded EGF repeats are not substrates (Figure 3b), we needed an independent measure of whether the S52A and S53A mutants were properly folded. We took advantage of the fact that O-FucT-1 also requires properly folded EGF repeats and that the factor VII EGF repeat contains an O-fucose glycosylation

![Diagram](https://example.com/diagram.png)

**Fig. 1.** O-glucose glycosylation pathway. Addition of O-glucose to the putative consensus site on EGF repeats by UDP-glucose: protein O-glucosyltransferase (as described), as well as elongation of O-glucose by UDP-glucose α1,3-xylosyltransferase (Omichi et al., 1997) and xylose α1,3-xylosyltransferase are shown (Minamida et al., 1996).
Protein \( \beta \)-glucosyltransferase (Harris and Spellman, 1993). Both the S52A and S53A mutants were essentially equivalent to wild type as a substrate for \( \beta \)-FucT-1 (Figure 3c), indicating that the mutant EGF repeats were properly folded. Analysis of the same mutant in the \( \beta \)-glucosyltransferase assay showed no activity for the S52A mutant, whereas the S53A mutant had nearly equivalent activity to wild type (Figure 3d). These results demonstrate that serine-52 is essential for addition of \( \beta \)-glucose to factor VII EGF repeat.

Product characterization

A series of chromatographic analyses were carried out to demonstrate that the product generated in the assays consists of glucose in \( \beta \)-linkage to the EGF repeat. To demonstrate that the glucose is covalently associated with the EGF repeat, the product was analyzed by reverse-phase HPLC (Figure 4a). Furthermore, to demonstrate that the glucose was attached through an \( \beta \)-linkage, alkali-induced \( \beta \)-elimination was performed. The released sugar product from the \( \beta \)-elimination migrated as a monosaccharide on gel filtration chromatography (Figure 4b). Analysis of the monosaccharide by high-performance anion-exchange chromatography (HPAEC) revealed it to be glucitol (Figure 4c), the expected product from \( \beta \)-elimination of \( \beta \)-glucose.

Optimization of \( \beta \)-glucosyltransferase assay

The \( \beta \)-glucosyltransferase assay was optimized for temperature, pH, and time. Product formation increased linearly with time, and, not surprisingly, the enzyme worked best at 37°C (Figure 5a, b). Different pH values of the reaction buffer affected the enzyme activity as well (Figure 5c), with an optimal range between pH 6 and 7.5. As with most glycosyltransferases, the \( \beta \)-glucosyltransferase requires metal ions for activity. In the absence of cations or in the presence of ethylenediamine tetra-acetic acid (EDTA), the \( \beta \)-glucosyltransferase had very little activity. Among those cations tested, manganese enhanced the activity the greatest; magnesium, calcium, and cobalt also supported some enzyme activity, whereas zinc did not (Figure 5d). Optimal activity was achieved at a concentration of 10 mM manganese (Figure 5e).

Distribution of \( \beta \)-glucosyltransferase activity

To address how widespread the \( \beta \)-glucose modification is in biology, we assayed extracts of cells from a variety of species and several tissues from rat for \( \beta \)-glucosyltransferase activity. Activity was detected in extracts of cells from all metazoans tested, although it was not detected in yeast (Figure 6a). Different pH values of the reaction buffer affected the enzyme activity as well (Figure 6a, b). Different pH values of the reaction buffer affected the enzyme activity as well (Figure 6b). Among those cations tested, manganese enhanced the activity the greatest; magnesium, calcium, and cobalt also supported some enzyme activity, whereas zinc did not (Figure 6c). Optimal activity was achieved at a concentration of 10 mM manganese (Figure 6d).

Fig. 2. \( \beta \)-glucosyltransferase activity is linearly dependent on the CHO cell lysate amount and the concentration of the substrates. (a) CHO cell lysate was varied with constant EGF and UDP-glucose concentration. (b) The concentrations of factor VII EGF were varied with constant CHO cell lysate and UDP-glucose concentration. (c) UDP-glucose was varied with constant EGF concentration and CHO cell lysate amount.

Fig. 3. Factor VII EGF repeat must be properly folded and contain the proper consensus sequence to be modified by \( \beta \)-glucosyltransferase. (a) After reduction and alkylation, factor VII EGF repeat was purified by reverse-phase HPLC. Elution times of the native and reduced and alkylated (denatured) EGF repeats are shown. (b) \( \beta \)-glucosyltransferase assays were performed using both control and denatured factor VII EGF repeat as in Figure 2b (circles: native EGF repeat; squares: reduced and alkylated EGF repeat). (c) The predicted \( \beta \)-glucose consensus site in factor VII EGF repeat was mutated (S52A and S53A) and analyzed for its ability to serve as a substrate for \( \beta \)-FucT-1 compared to wild-type factor VII EGF repeat (circles: wild-type EGF repeat; squares: S52A mutant; triangles: S53A mutant). (d) Mutated factor VII EGF repeat was analyzed in an \( \beta \)-glucosyltransferase assay as in Figure 2b (circles: wild-type EGF repeat; squares: S52A mutant; triangles: S53A mutant).
activity is found in both vertebrate and invertebrate species and that the invertebrate enzymes can recognize the glycosylation site in the EGF repeat from a vertebrate. Analysis of the rat tissue extracts (heart, liver, lung, leg muscle, kidney, spleen, and brain) suggested that this enzyme is also widely expressed in tissues (Figure 6b), although the specific activity varies. The highest activity was found in the extract of spleen and brain, and lowest in heart and leg muscle.

Discussion

In this article, we develop an assay for and initially characterize the UDP-glucose: protein O-glucosyltransferase. Like O-FucT-1 (Wang et al., 2001; Wang and Spellman, 1998), the O-glucosyltransferase requires a properly folded EGF repeat as an acceptor substrate. The activity requires metal ions, and optimal activity is between pH 6 and 7.5. The enzyme activity could be detected in a wide variety of tissues and metazoan species, indicating that this unusual modification is widespread in biology. Identification of this enzyme is an essential step toward a full understanding of the biological significance of the O-glucose modification.

Although the biological effect of modifying EGF repeats with O-glucose is not yet known, recent work on the O-fucose modifications of the Notch receptor (Moloney et al., 2000a), uPA (Rabbani et al., 1992), and Cripto (Schiffer et al., 2001; Yan et al., 2002) demonstrates that carbohydrate modifications of EGF repeats can regulate receptor–ligand interactions. If a simple O-fucose monosaccharide can alter the interaction between receptor and ligand, the more complex O-glucose modifications on the EGF repeats may have similar effects. Several observations suggest such a role for O-glucose modifications. For instance, mutation of serine-52 (the O-glucose site) to alanine in human blood coagulation factor VII results in a decrease in factor VII clotting activity by an unknown mechanism (Bjoern et al., 1991). The conservation across species of O-glucose consensus sites on many of the proteins either known or predicted to be modified (Table I) strongly suggests that O-glucose plays an essential role in the function of these proteins. This is most apparent in the Notch receptor. Although Notch activity is regulated by Fringe through alteration of the O-fucose residues, Notch contains more conserved O-glucose sites than O-fucose sites (Moloney et al., 2000b). Comparison of all Notch sequences currently in the database reveals 5 evolutionarily conserved O-fucose sites (EGF modules 3, 20, 24, 26, 31) and 12 evolutionarily conserved O-glucose sites (EGF modules 4, 10, 12, 13, 14, 16, 19, 20, 21, 25, 27, 33).

The Notch receptor protein is extremely important for its role in numerous stages of development (Artavanis-Tsakonas et al., 1999). In Drosophila, Notch is one of several neurogenic genes that mediate cell fate decisions during development. Targeted disruption of the Notch1 gene in mice causes embryonic lethality (Swiatek et al., 1994). In humans, deregulation of Notch signaling results in serious diseases, such as T cell
Protein O-glucosyltransferase

Only two forms of β-linked glucose modifications are known to exist on mammalian glycoproteins, including O-glucose and the disaccharide Glcβ1,3Fuc-O-Ser/Thr. Several years ago we demonstrated the presence of the Glcβ1,3Fuc disaccharide O-linked to a number of proteins in CHO cells (Moloney et al., 1997) and identified a β1,3-glucosyltransferase activity capable of adding the glucose to fucose (Moloney and Haltrwanger, 1999). We had originally believed these disaccharides to exist on EGF repeats, because O-fucose was only known on EGF repeats at that time. A recent elegant study by Hofsteenge and co-workers (2001) using mass spectral analysis of thrombospondin-1 revealed the presence of two unusual carbohydrate modifications: C-linked mannose on several tryptophans and the O-linked disaccharide Glc-Fuc on several serine/threonine residues. This work demonstrated that Glc-Fuc disaccharides are not on EGF repeats, but instead are found on a different type of protein domain called a thrombospondin-type 1 repeat (TSR) (Adams and Tucker, 2000). Neither the enzyme responsible for addition of O-fucose to the TSR nor the biological function of this modification is yet known.

The anomeric linkage of O-glucose was established in a single study (Hase et al., 1990) where nuclear magnetic resonance (NMR) was utilized to analyze the structure of the O-glucose modification on bovine factor IX. No other data on the anomeric linkage of O-glucose exists. In particular, no successful enzymatic cleavage of O-glucose from protein has been reported. We have been unsuccessful in several attempts to remove O-glucose from factor VII EGF repeat or glycopeptides derived from glycosylated EGF repeat using either α- or β-glucosidases, suggesting that this linkage is uniquely resistant to enzymatic digestion. Although the O-glucose on factor VII EGF repeat is likely to be β-linked, definitive demonstration of the linkage awaits production of sufficient product to pursue NMR analysis.

Unusual carbohydrate modifications are often related to a specific biological event (Varki, 1993). For example, mannose 6-phosphatetargets lysosomal enzymes to lysosomes (Kornfeld, 1990), sialyl Lewis x helps recruit leukocytes to sites of inflammation (Zak et al., 2000), and polysialic acid modulates neural cell adhesion molecule interactions during neuronal development (Acheson et al., 1991). The recent work demonstrating O-fucose modifications on the EGF repeats of Notch, uPA, and Cripto play a role in signaling events provides other clear examples of a rare form of glycosylation performing a specific biological function. The O-glucose modifications of EGF repeats are another unusual form of glycosylation that we predict will have an equally specific role in the biology of the proteins it modifies. We have initiated attempts to purify the O-glucosyltransferase by using a combination of conventional and affinity chromatography. Purifying and cloning this enzyme will allow us to develop the tools necessary to study this unique modification.

Materials and methods

Materials

UDP-[6-3H]glucose was purchased from Sigma. UDP-[6-3H]glucose (60 Ci/mmol) was purchased from American Radio-labeled Chemicals (St. Louis, MO). Human factor VII EGF

Fig. 6. O-glucosyltransferase is expressed in a wide variety of metazoans and mammalian tissues. (a) O-glucosyltransferase activity was assayed in lysates of a variety of different cultured cells. CHO, Chinese hamster ovary epithelial; HD11, chicken macrophage; NIH 3T3, mouse embryo fibroblast; Hela, human cervical carcinoma; S2: Schneidar cell; SF-9, fall armyworm. (b) O-glucosyltransferase activity was assayed in lysates of normal adult rat tissues.
was both kindly provided by Dr. Yang Wang (Genentech, San Francisco, CA) and synthesized as described later. The CHO Lec1 cell line was developed by Pamela Stanley (Stanley and Siminovitch, 1977). Lec1, Hela, SF-9, S2, and NIH3T3 cells were from American Type Culture Collection (Rockville, MD). HD11 cells (Beug et al., 1979) were kindly provided by Dr. Michael Hayman (Department of Microbiology, SUNY Stony Brook). Alditol sugar standards were prepared by reduction of the corresponding sugar with sodium borohydride as described elsewhere (Haltiwanger et al., 1990). C18 cartridges were obtained from Waters Associated (Milford, MA). Reverse-phase C18 HPLC columns (4.6 × 250 mm; Dyanamax) were purchased from Rainin (Woburn, MA). Protease inhibitor cocktails I and II were prepared as described elsewhere (Holt and Hart, 1986). All other reagents were of the highest quality available.

Preparation of cell lysates and rat tissues

All mammalian cells were grown in 100-mm dishes in a humidified 37°C incubator with 5% CO₂. Lec1 cells were grown in αMEM medium (Mediatech, Herndon, VA) supplemented with 10% fetal bovine serum (HyClone, Logan, UT). Hela and NIH3T3 cells were grown in Dulbecco’s modified Eagle’s medium (Gibco, Life Technologies, Rockville, MD) supplemented with 10% fetal bovine serum. SF-9 cells were grown at room temperature in Grace’s insect medium (Gibco, Life Technologies) supplemented with 10% fetal bovine serum. S2 cells were also grown at room temperature in Shields and Sang M3 insect medium (Sigma) with 10% fetal bovine serum. SF-9 cells were also grown at room temperature in Grace’s insect medium (Gibco, Life Technologies) supplemented with 10% fetal bovine serum. S2 cells were also grown at room temperature in Shields and Sang M3 insect medium (Sigma) with 10% fetal bovine serum. Cells were collected by scraping and washed three times with Tris-buffered saline (10 mM Tris–HCl, pH 7.5, 0.15 M NaCl). Yeast cell pellets were generously provided by Rolf Sternglanz (Department of Biochemistry and Cell Biology, SUNY Stony Brook). Cell pellets were lysed on ice in Tris-buffered saline with 1% (w/v) Nonidet P-40 and protease inhibitors (by Rolf Sternglanz, Department of Biochemistry and Cell Biology, SUNY Stony Brook). Alditol sugar standards were prepared by reduction of the corresponding sugar with sodium borohydride as described elsewhere (Haltiwanger et al., 1990). C18 cartridges were obtained from Waters Associated (Milford, MA). Reverse-phase C18 HPLC columns (4.6 × 250 mm; Dyanamax) were purchased from Rainin (Woburn, MA). Protease inhibitor cocktails I and II were prepared as described elsewhere (Holt and Hart, 1986). All other reagents were of the highest quality available.

Preparation of cell lysates and rat tissues

All mammalian cells were grown in 100-mm dishes in a humidified 37°C incubator with 5% CO₂. Lec1 cells were grown in αMEM medium (Mediatech, Herndon, VA) supplemented with 10% fetal bovine serum (HyClone, Logan, UT). Hela and NIH3T3 cells were grown in Dulbecco’s modified Eagle’s medium (Gibco, Life Technologies, Rockville, MD) supplemented with 10% fetal bovine serum. SF-9 cells were grown at room temperature in Grace’s insect medium (Gibco, Life Technologies) supplemented with 10% fetal bovine serum. S2 cells were also grown at room temperature in Shields and Sang M3 insect medium (Sigma) with 10% fetal bovine serum. Cells were collected by scraping and washed three times with Tris-buffered saline (10 mM Tris–HCl, pH 7.5, 0.15 M NaCl). Yeast cell pellets were generously provided by Rolf Sternglanz (Department of Biochemistry and Cell Biology, SUNY Stony Brook). Cell pellets were lysed on ice in Tris-buffered saline with 1% (w/v) Nonidet P-40 and protease inhibitors (by Rolf Sternglanz, Department of Biochemistry and Cell Biology, SUNY Stony Brook). Alditol sugar standards were prepared by reduction of the corresponding sugar with sodium borohydride as described elsewhere (Haltiwanger et al., 1990). C18 cartridges were obtained from Waters Associated (Milford, MA). Reverse-phase C18 HPLC columns (4.6 × 250 mm; Dyanamax) were purchased from Rainin (Woburn, MA). Protease inhibitor cocktails I and II were prepared as described elsewhere (Holt and Hart, 1986). All other reagents were of the highest quality available.

Preparation of cell lysates and rat tissues

All mammalian cells were grown in 100-mm dishes in a humidified 37°C incubator with 5% CO₂. Lec1 cells were grown in αMEM medium (Mediatech, Herndon, VA) supplemented with 10% fetal bovine serum (HyClone, Logan, UT). Hela and NIH3T3 cells were grown in Dulbecco’s modified Eagle’s medium (Gibco, Life Technologies, Rockville, MD) supplemented with 10% fetal bovine serum. SF-9 cells were grown at room temperature in Grace’s insect medium (Gibco, Life Technologies) supplemented with 10% fetal bovine serum. S2 cells were also grown at room temperature in Shields and Sang M3 insect medium (Sigma) with 10% fetal bovine serum. Cells were collected by scraping and washed three times with Tris-buffered saline (10 mM Tris–HCl, pH 7.5, 0.15 M NaCl). Yeast cell pellets were generously provided by Rolf Sternglanz (Department of Biochemistry and Cell Biology, SUNY Stony Brook). Cell pellets were lysed on ice in Tris-buffered saline with 1% (w/v) Nonidet P-40 and protease inhibitors (by Rolf Sternglanz, Department of Biochemistry and Cell Biology, SUNY Stony Brook). Alditol sugar standards were prepared by reduction of the corresponding sugar with sodium borohydride as described elsewhere (Haltiwanger et al., 1990). C18 cartridges were obtained from Waters Associated (Milford, MA). Reverse-phase C18 HPLC columns (4.6 × 250 mm; Dyanamax) were purchased from Rainin (Woburn, MA). Protease inhibitor cocktails I and II were prepared as described elsewhere (Holt and Hart, 1986). All other reagents were of the highest quality available.

Preparation of cell lysates and rat tissues

All mammalian cells were grown in 100-mm dishes in a humidified 37°C incubator with 5% CO₂. Lec1 cells were grown in αMEM medium (Mediatech, Herndon, VA) supplemented with 10% fetal bovine serum (HyClone, Logan, UT). Hela and NIH3T3 cells were grown in Dulbecco’s modified Eagle’s medium (Gibco, Life Technologies, Rockville, MD) supplemented with 10% fetal bovine serum. SF-9 cells were grown at room temperature in Grace’s insect medium (Gibco, Life Technologies) supplemented with 10% fetal bovine serum. S2 cells were also grown at room temperature in Shields and Sang M3 insect medium (Sigma) with 10% fetal bovine serum. Cells were collected by scraping and washed three times with Tris-buffered saline (10 mM Tris–HCl, pH 7.5, 0.15 M NaCl). Yeast cell pellets were generously provided by Rolf Sternglanz (Department of Biochemistry and Cell Biology, SUNY Stony Brook). Cell pellets were lysed on ice in Tris-buffered saline with 1% (w/v) Nonidet P-40 and protease inhibitors (by Rolf Sternglanz, Department of Biochemistry and Cell Biology, SUNY Stony Brook). Alditol sugar standards were prepared by reduction of the corresponding sugar with sodium borohydride as described elsewhere (Haltiwanger et al., 1990). C18 cartridges were obtained from Waters Associated (Milford, MA). Reverse-phase C18 HPLC columns (4.6 × 250 mm; Dyanamax) were purchased from Rainin (Woburn, MA). Protease inhibitor cocktails I and II were prepared as described elsewhere (Holt and Hart, 1986). All other reagents were of the highest quality available.

Preparation of cell lysates and rat tissues

All mammalian cells were grown in 100-mm dishes in a humidified 37°C incubator with 5% CO₂. Lec1 cells were grown in αMEM medium (Mediatech, Herndon, VA) supplemented with 10% fetal bovine serum (HyClone, Logan, UT). Hela and NIH3T3 cells were grown in Dulbecco’s modified Eagle’s medium (Gibco, Life Technologies, Rockville, MD) supplemented with 10% fetal bovine serum. SF-9 cells were grown at room temperature in Grace’s insect medium (Gibco, Life Technologies) supplemented with 10% fetal bovine serum. S2 cells were also grown at room temperature in Shields and Sang M3 insect medium (Sigma) with 10% fetal bovine serum. Cells were collected by scraping and washed three times with Tris-buffered saline (10 mM Tris–HCl, pH 7.5, 0.15 M NaCl). Yeast cell pellets were generously provided by Rolf Sternglanz (Department of Biochemistry and Cell Biology, SUNY Stony Brook). Cell pellets were lysed on ice in Tris-buffered saline with 1% (w/v) Nonidet P-40 and protease inhibitors (by Rolf Sternglanz, Department of Biochemistry and Cell Biology, SUNY Stony Brook). Alditol sugar standards were prepared by reduction of the corresponding sugar with sodium borohydride as described elsewhere (Haltiwanger et al., 1990). C18 cartridges were obtained from Waters Associated (Milford, MA). Reverse-phase C18 HPLC columns (4.6 × 250 mm; Dyanamax) were purchased from Rainin (Woburn, MA). Protease inhibitor cocktails I and II were prepared as described elsewhere (Holt and Hart, 1986). All other reagents were of the highest quality available.

Preparation of cell lysates and rat tissues

All mammalian cells were grown in 100-mm dishes in a humidified 37°C incubator with 5% CO₂. Lec1 cells were grown in αMEM medium (Mediatech, Herndon, VA) supplemented with 10% fetal bovine serum (HyClone, Logan, UT). Hela and NIH3T3 cells were grown in Dulbecco’s modified Eagle’s medium (Gibco, Life Technologies, Rockville, MD) supplemented with 10% fetal bovine serum. SF-9 cells were grown at room temperature in Grace’s insect medium (Gibco, Life Technologies) supplemented with 10% fetal bovine serum. S2 cells were also grown at room temperature in Shields and Sang M3 insect medium (Sigma) with 10% fetal bovine serum. Cells were collected by scraping and washed three times with Tris-buffered saline (10 mM Tris–HCl, pH 7.5, 0.15 M NaCl). Yeast cell pellets were generously provided by Rolf Sternglanz (Department of Biochemistry and Cell Biology, SUNY Stony Brook). Cell pellets were lysed on ice in Tris-buffered saline with 1% (w/v) Nonidet P-40 and protease inhibitors (by Rolf Sternglanz, Department of Biochemistry and Cell Biology, SUNY Stony Brook). Alditol sugar standards were prepared by reduction of the corresponding sugar with sodium borohydride as described elsewhere (Haltiwanger et al., 1990). C18 cartridges were obtained from Waters Associated (Milford, MA). Reverse-phase C18 HPLC columns (4.6 × 250 mm; Dyanamax) were purchased from Rainin (Woburn, MA). Protease inhibitor cocktails I and II were prepared as described elsewhere (Holt and Hart, 1986). All other reagents were of the highest quality available.
Product analysis by gel filtration chromatography and HPAEC
Radiolabeled product in the eluant from the glucosyltransferase assay was dried in a Speed-Vac. Alkali-induced β-elimination, gel filtration on Superdex column, and HPAEC analysis of the products on a Carboxap MA-1 column (Dionex, Sunnyvale, CA) were all done as described (Moloney et al., 1997, 2000b)

Acknowledgments
The authors would like to thank Annie Li, Malgosia Kokoszka, and Raajit Rampal for critical reading and helpful discussions. We also thank Dr. Michael Hayman and Dr. Sternglanz for providing the HD11 and yeast cells, respectively. This work was supported by National Institutes of Health grant GM 61126.

Abbreviations
EGF, epidermal growth factor-like; CHO, Chinese hamster ovary; DTt, diithiothreitol; EDTA, ethylenediamine tetraacetic acid; HPAEC, high pH anion-exchange chromatography; HPLC, high-performance liquid chromatography; NMR, nuclear magnetic resonance; O-FucT-1, O-fucosyltransferase; TSR, thrombospondin type 1 repeat; uPA, urinary-type plasminogen activator.

References


